MX2012003063A - Proceso para la sintesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2', 4',5',7'-tetrayodo-3h-espiro[isobenzofuran-1,9'-xanten]-3-ona (rosa de bengala) y xantenos relacionados. - Google Patents

Proceso para la sintesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2', 4',5',7'-tetrayodo-3h-espiro[isobenzofuran-1,9'-xanten]-3-ona (rosa de bengala) y xantenos relacionados.

Info

Publication number
MX2012003063A
MX2012003063A MX2012003063A MX2012003063A MX2012003063A MX 2012003063 A MX2012003063 A MX 2012003063A MX 2012003063 A MX2012003063 A MX 2012003063A MX 2012003063 A MX2012003063 A MX 2012003063A MX 2012003063 A MX2012003063 A MX 2012003063A
Authority
MX
Mexico
Prior art keywords
new
tetraiodo
xanthen
isobenzofuran
tetrachloro
Prior art date
Application number
MX2012003063A
Other languages
English (en)
Spanish (es)
Inventor
Jamie Singer
Eric A Wachter
Timothy C Scott
Marlon Lutz
Kevin Babiak
Original Assignee
Provectus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provectus Pharmaceuticals Inc filed Critical Provectus Pharmaceuticals Inc
Publication of MX2012003063A publication Critical patent/MX2012003063A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C07D311/82—Xanthenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
MX2012003063A 2009-09-18 2010-09-17 Proceso para la sintesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2', 4',5',7'-tetrayodo-3h-espiro[isobenzofuran-1,9'-xanten]-3-ona (rosa de bengala) y xantenos relacionados. MX2012003063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24370109P 2009-09-18 2009-09-18
PCT/US2010/049341 WO2011035161A1 (en) 2009-09-18 2010-09-17 Process for the synthesis of 4,5,6,7-tetrachloro-3',6'-dihydroxy-2',4',5'7'-tetraiodo-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one (rose bengal) and related xanthenes

Publications (1)

Publication Number Publication Date
MX2012003063A true MX2012003063A (es) 2012-07-25

Family

ID=43757167

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003063A MX2012003063A (es) 2009-09-18 2010-09-17 Proceso para la sintesis de 4,5,6,7-tetracloro-3',6'-dihidroxi-2', 4',5',7'-tetrayodo-3h-espiro[isobenzofuran-1,9'-xanten]-3-ona (rosa de bengala) y xantenos relacionados.

Country Status (9)

Country Link
US (2) US8530675B2 (cg-RX-API-DMAC10.html)
EP (1) EP2464225B8 (cg-RX-API-DMAC10.html)
JP (1) JP5671040B2 (cg-RX-API-DMAC10.html)
KR (1) KR101494055B1 (cg-RX-API-DMAC10.html)
CN (1) CN102548406B (cg-RX-API-DMAC10.html)
CA (1) CA2771988C (cg-RX-API-DMAC10.html)
ES (1) ES2548575T3 (cg-RX-API-DMAC10.html)
MX (1) MX2012003063A (cg-RX-API-DMAC10.html)
WO (1) WO2011035161A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
US20150111301A1 (en) * 2013-10-22 2015-04-23 The Government Of The United States As Represented By The Secretary Of The Air Force Rose bengal for detection of oxidative decomposition of contaminants
JP7015232B2 (ja) * 2018-11-21 2022-02-02 東レ・ファインケミカル株式会社 高純度のフルオレセイン類化合物の製造方法
EP3931197B1 (en) * 2019-02-26 2024-04-24 F. Hoffmann-La Roche AG Process for the preparation of (6s)-3-[(4s)-4-cyano-2-oxo-pyrrolidin-1-yl]-6-methyl-n-(3,4,5-trifluorophenyl)-6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine-5-carboxamide
WO2021195400A1 (en) 2020-03-26 2021-09-30 Provectus Pharmatech, Inc. Novel uses of halogenated xanthenes in oncology and virology
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants
AU2022425066A1 (en) 2021-12-28 2024-06-06 Provectus Pharmatech, Inc Photodynamic anti-gram-positive bacterial activity of pharmaceutical-grade rose bengal
CN120957716A (zh) * 2023-03-29 2025-11-14 普罗维克图斯药品技术公司 卤化荧光素对耐粘菌素革兰氏阴性菌的抗细菌作用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE108838C (cg-RX-API-DMAC10.html)
US1965842A (en) * 1931-11-21 1934-07-10 Nat Aniline & Chem Co Inc Production of hydroxybenzenephthaleins
US1931049A (en) * 1931-11-21 1933-10-17 Nat Aniline & Chem Co Inc Process of making dihydroxyfluoranes
US3829440A (en) * 1972-12-21 1974-08-13 Richardson Merrell Inc Xanthene derivatives
SU517222A1 (ru) 1974-10-25 1977-06-25 Институт Биофизики Министерства Здравохранения Ссср Способ получени препарата бенгальска роза, меченного радиоизотопами йода
SU792878A1 (ru) 1978-08-29 1982-02-07 Ленинградский институт ядерной физики им. Б.П.Константинова Способ получени галогенированных производных флуоресцеина,меченных радиоизотопом йода
EP0050684B1 (en) 1980-10-27 1986-01-22 Syva Company Novel ether substituted fluorescein compounds as fluorescers and quenchers
SU992516A1 (ru) 1981-06-11 1983-01-30 Ленинградский Институт Ядерной Физики Им.Б.П.Константинова Способ получени галогенированных производных флуоресцеина,меченных радиоизотопом иода -123
ES8606451A1 (es) 1985-10-28 1986-04-16 Zoster Sa Procedimiento para la obtencion de la eritrosina sodica
IN168346B (cg-RX-API-DMAC10.html) 1987-09-07 1991-03-16 Council Scient Ind Res
US5637733A (en) * 1995-09-27 1997-06-10 Warner-Jenkinson Company, Inc. Syntheses of fluorescein compounds with excess resorcinol as a solvent
US6252024B1 (en) * 1995-10-23 2001-06-26 Novartis Ag Fluorescent N-alkylated acrylamide copolymers and optical pH sensors
US6162931A (en) 1996-04-12 2000-12-19 Molecular Probes, Inc. Fluorinated xanthene derivatives
US5945526A (en) * 1996-05-03 1999-08-31 Perkin-Elmer Corporation Energy transfer dyes with enhanced fluorescence
US6331286B1 (en) 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
US7648695B2 (en) 1998-08-06 2010-01-19 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6372907B1 (en) * 1999-11-03 2002-04-16 Apptera Corporation Water-soluble rhodamine dye peptide conjugates
US6448407B1 (en) * 2000-11-01 2002-09-10 Pe Corporation (Ny) Atropisomers of asymmetric xanthene fluorescent dyes and methods of DNA sequencing and fragment analysis
AU2002256991A1 (en) * 2001-02-05 2002-08-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Use of 9h-xanthenes in a method of inhibiting viral replication targeting the nucleocapsid protein
US6800765B2 (en) * 2001-08-02 2004-10-05 Molecular Devices Corporation Fluorescent pH indicators for intracellular assays
CA2490961A1 (en) * 2002-07-01 2004-01-08 Guava Technologies, Inc. Fluorescent dyes, energy transfer couples and methods
FR2846331B1 (fr) * 2002-10-29 2006-11-17 Synth Innove Lab Phtaleines de purete elevee et leur procede de preparation
WO2004078874A2 (en) * 2003-02-28 2004-09-16 Polaroid Corporation Novel dye complexes and use thereof in imaging members and methods
EP1753467B1 (en) * 2004-06-10 2013-01-09 Provectus Pharmatech, Inc. Diagnostic agents for positron emission imaging using radiolabeled halogenated xanthenes and methods for positron emission imaging with radiolabeled halogenated xanthene diagnostic agents
CA2657691A1 (en) * 2006-06-19 2007-12-27 Vanderbilt University Methods and compositions for diagnostic and therapeutic targeting of cox-2
GB0613287D0 (en) * 2006-07-05 2006-08-16 Ge Healthcare Ltd Dye imaging agents
ITMI20061713A1 (it) * 2006-09-08 2008-03-09 St Microelectronics Srl Procedimento per la sintesi di derivati alogenati della fluoresceina utili nella produzione di dispositivi di memoria non volatile

Also Published As

Publication number Publication date
KR20120091088A (ko) 2012-08-17
US9422260B2 (en) 2016-08-23
EP2464225A4 (en) 2013-03-27
EP2464225B1 (en) 2015-09-16
US20110071217A1 (en) 2011-03-24
CA2771988A1 (en) 2011-03-24
JP5671040B2 (ja) 2015-02-18
CA2771988C (en) 2016-07-05
EP2464225A1 (en) 2012-06-20
KR101494055B1 (ko) 2015-02-16
EP2464225B8 (en) 2017-08-23
HK1172501A1 (en) 2013-04-26
CN102548406A (zh) 2012-07-04
ES2548575T3 (es) 2015-10-19
WO2011035161A1 (en) 2011-03-24
US20130274322A1 (en) 2013-10-17
US8530675B2 (en) 2013-09-10
JP2013505261A (ja) 2013-02-14
HK1172212A1 (zh) 2013-04-19
CN102548406B (zh) 2015-04-08

Similar Documents

Publication Publication Date Title
WO2008048990A3 (en) Processes suitable for producing macromolecular antioxidant compositions
JP6389565B2 (ja) カルコブトロールの製造方法
JO2910B1 (en) Organic compounds
NO20055688L (no) Organiske forbindelser
MY158421A (en) Process for the preparation of calcobutrol
WO2011077099A3 (en) Methods for the purification of cucurbituril
CY1111327T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλοξεικου οξεος
EA201290405A1 (ru) Способ и установка для создания однородного перемешивания в связи с гидрометаллургическим процессом
EA201070804A1 (ru) (аза)индольное производное, замещенное по положению 5, содержащая его фармацевтическая композиция, промежуточные соединения и способ их получения
Nam et al. Synthesis of aminoalkyl-substituted coumarin derivatives as acetylcholinesterase inhibitors
MX2014005870A (es) Proceso para preparar compuestos de 1h -pirazol - 5 - carboxilato n - sustituidos y derivados de los mismos.
IN2012DN03176A (cg-RX-API-DMAC10.html)
JP2017538770A (ja) ガドブトロールの製造方法
EA201001395A1 (ru) Специфичные примеси монтелукаста
Yoshida et al. Regulatory molecules for the 5-HT3 receptor ion channel gating system
UA90188C2 (ru) Способ выделения кислот из реакционных смесей и способ получения триамидов тиофосфорной кислоты
Vallejo et al. N-Demethyl-sauroxine, a novel Lycodine Group alkaloid from Huperzia saururus
HK1172212A1 (zh) 合成4,5,6,7四氯-3',6'-二羥基-2',4',5',7'-四碘-3h-螺[異苯並呋喃-1,9'-呫噸]-3-酮(玫瑰紅)及相關呫噸
PT1611139E (pt) Métodos de preparação de olanzapina
Yin et al. Botryllamides K and L, new tyrosine derivatives from the Australian ascidian Aplidium altarium
PL1745010T3 (pl) Podstawione pochodne cykloheksylo-1,4-diaminy
WO2006031782A3 (en) Salvinorin derivatives as opioid receptor ligands
DE112007000952A5 (de) Verfahren zur Herstellung von Wasserstoffreichen Silanen, sowie neue chemische Verbindungen
AU2014326601A1 (en) Preparation of radioiodinated 3-fluoropropyl-nor-beta-CIT
TW200611901A (en) Method for producing 1, 3-dioxolan-4, 6-dione compound